{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:40:43Z","timestamp":1792100443762,"version":"4.4.0"},"reference-count":49,"publisher":"American Medical Association (AMA)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Venous thromboembolism (VTE) is a leading cause of morbidity and mortality after bariatric surgery. Clinical end point studies on thromboprophylaxis with direct oral anticoagulants in patients undergoing bariatric surgery are lacking.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the efficacy and safety of a prophylactic dose of 10 mg\/d of rivaroxaban for both 7 and 28 days after bariatric surgery.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This assessor-blinded, phase 2, multicenter randomized clinical trial was conducted from July 1, 2018, through June 30, 2021, with participants from 3 academic and nonacademic hospitals in Switzerland.<\/jats:p>\n <\/jats:sec>\n \n Intervention<\/jats:title>\n Patients were randomized 1 day after bariatric surgery to 10 mg of oral rivaroxaban for either 7 days (short prophylaxis) or 28 days (long prophylaxis).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary efficacy outcome was the composite of deep vein thrombosis (symptomatic or asymptomatic) and pulmonary embolism within 28 days after bariatric surgery. Main safety outcomes included major bleeding, clinically relevant nonmajor bleeding, and mortality.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Of 300 patients, 272 (mean [SD] age, 40.0 [12.1] years; 216 women [80.3%]; mean body mass index, 42.2) were randomized; 134 received a 7-day and 135 a 28-day VTE prophylaxis course with rivaroxaban. Only 1 thromboembolic event (0.4%) occurred (asymptomatic thrombosis in a patient undergoing sleeve gastrectomy with extended prophylaxis). Major or clinically relevant nonmajor bleeding events were observed in 5 patients (1.9%): 2 in the short prophylaxis group and 3 in the long prophylaxis group. Clinically nonsignificant bleeding events were observed in 10 patients (3.7%): 3 in the short prophylaxis arm and 7 in the long prophylaxis arm.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this randomized clinical trial, once-daily VTE prophylaxis with 10 mg of rivaroxaban was effective and safe in the early postoperative phase after bariatric surgery in both the short and long prophylaxis groups.<\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03522259<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.15241","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T11:33:45Z","timestamp":1685014425000},"page":"e2315241","source":"Crossref","is-referenced-by-count":32,"title":["Efficacy and Safety of Rivaroxaban for Postoperative Thromboprophylaxis in Patients After Bariatric Surgery"],"prefix":"10.1001","volume":"6","author":[{"given":"Dino","family":"Kr\u00f6ll","sequence":"first","affiliation":[{"name":"Department of Visceral Surgery and Medicine, Bern University Hospital (Inselspital) and University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp C.","family":"Nett","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery and Medicine, Bern University Hospital (Inselspital) and University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikki","family":"Rommers","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, Clinical Trial Unit, University of Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Borb\u00e9ly","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery and Medicine, Bern University Hospital (Inselspital) and University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Deichsel","sequence":"additional","affiliation":[{"name":"Department of Surgery, Cantonal Hospital of Baden, Baden, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Nocito","sequence":"additional","affiliation":[{"name":"Department of Surgery, Cantonal Hospital of Baden, Baden, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Zehetner","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery, Hirslanden Clinic Beau-Site, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Kessler","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery, Hirslanden Clinic Beau-Site, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yannick","family":"Fringeli","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery, Hirslanden Clinic Beau-Site, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenzo","family":"Alberio","sequence":"additional","affiliation":[{"name":"Division of Haematology and Central Haematology Laboratory, Centre Hospitalier Universitaire Vaudois, University of Lausanne, Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Candinas","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery and Medicine, Bern University Hospital (Inselspital) and University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Stirnimann","sequence":"additional","affiliation":[{"name":"Department of Visceral Surgery and Medicine, Bern University Hospital (Inselspital) and University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"issue":"12","key":"zoi230469r1","doi-asserted-by":"publisher","first-page":"3783","DOI":"10.1007\/s11695-018-3450-2","article-title":"IFSO Worldwide Survey 2016: primary, endoluminal, and revisional procedures.","volume":"28","author":"Angrisani","year":"2018","journal-title":"Obes Surg"},{"issue":"2","key":"zoi230469r2","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1097\/SLA.0000000000003554","article-title":"Changes in utilization of bariatric surgery in the United States From 1993 to 2016.","volume":"271","author":"Campos","year":"2020","journal-title":"Ann Surg"},{"issue":"2","key":"zoi230469r3","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1111\/dom.2015.17.issue-2","article-title":"How safe is metabolic\/diabetes surgery?","volume":"17","author":"Aminian","year":"2015","journal-title":"Diabetes Obes Metab"},{"issue":"22","key":"zoi230469r4","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1001\/jama.2014.5988","article-title":"Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications.","volume":"311","author":"Sj\u00f6str\u00f6m","year":"2014","journal-title":"JAMA"},{"issue":"3","key":"zoi230469r5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/nrcardio.2013.211","article-title":"Inherited risk factors for venous thromboembolism.","volume":"11","author":"Martinelli","year":"2014","journal-title":"Nat Rev Cardiol"},{"issue":"23","key":"zoi230469r6","first-page":"I4","article-title":"The epidemiology of venous thromboembolism.","volume":"107","author":"White","year":"2003","journal-title":"Circulation"},{"issue":"11","key":"zoi230469r7","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1007\/s11695-013-1073-1","article-title":"Incidence of venous thromboembolism after bariatric surgery: a population-based cohort study.","volume":"23","author":"Froehling","year":"2013","journal-title":"Obes Surg"},{"issue":"1","key":"zoi230469r8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.soard.2006.10.002","article-title":"Venous thromboembolism in bariatric surgery patients: an update of risk and prevention.","volume":"3","author":"Hamad","year":"2007","journal-title":"Surg Obes Relat Dis"},{"issue":"1","key":"zoi230469r9","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/SLA.0000000000001686","article-title":"Who should get extended thromboprophylaxis after bariatric surgery? a risk assessment tool to guide indications for post-discharge pharmacoprophylaxis.","volume":"265","author":"Aminian","year":"2017","journal-title":"Ann Surg"},{"issue":"9","key":"zoi230469r10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1080\/17474086.2019.1634542","article-title":"Bariatric venous thromboembolism prophylaxis: an update on the literature.","volume":"12","author":"Hamadi","year":"2019","journal-title":"Expert Rev Hematol"},{"issue":"2","key":"zoi230469r11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.soard.2010.12.008","article-title":"Venous thromboembolism after bariatric surgery performed by Bariatric Surgery Center of Excellence Participants: analysis of the Bariatric Outcomes Longitudinal Database.","volume":"7","author":"Winegar","year":"2011","journal-title":"Surg Obes Relat Dis"},{"issue":"2","key":"zoi230469r12","doi-asserted-by":"publisher","first-page":"e227S","DOI":"10.1378\/chest.11-2297","article-title":"Prevention of VTE in nonorthopedic surgical patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.","volume":"141","author":"Gould","year":"2012","journal-title":"Chest"},{"issue":"2","key":"zoi230469r13","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.soard.2021.10.023","article-title":"The American Society for Metabolic and Bariatric Surgery (ASMBS) updated position statement on perioperative venous thromboembolism prophylaxis in bariatric surgery.","volume":"18","author":"Aminian","year":"2022","journal-title":"Surg Obes Relat Dis"},{"issue":"11","key":"zoi230469r14","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1007\/s00464-008-0031-9","article-title":"The effect of extended post-discharge chemical thromboprophylaxis on venous thromboembolism rates after bariatric surgery: a prospective comparison trial.","volume":"22","author":"Raftopoulos","year":"2008","journal-title":"Surg Endosc"},{"issue":"10","key":"zoi230469r15","doi-asserted-by":"publisher","first-page":"1368","DOI":"10.1381\/096089205774859245","article-title":"Enoxaparin for thromboprophylaxis in morbidly obese patients undergoing bariatric surgery: findings of the prophylaxis against VTE outcomes in bariatric surgery patients receiving enoxaparin (PROBE) study.","volume":"15","author":"Hamad","year":"2005","journal-title":"Obes Surg"},{"issue":"4","key":"zoi230469r16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1097\/SLA.0000000000002285","article-title":"To what extent does posthospital discharge chemoprophylaxis prevent venous thromboembolism after bariatric surgery? results from a nationwide cohort of more than 110,000 patients.","volume":"267","author":"Thereaux","year":"2018","journal-title":"Ann Surg"},{"issue":"2","key":"zoi230469r17","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.soard.2016.08.497","article-title":"Perioperative thromboprophylaxis in severely obese patients undergoing bariatric surgery: insights from a French national survey.","volume":"13","author":"Moulin","year":"2017","journal-title":"Surg Obes Relat Dis"},{"issue":"2","key":"zoi230469r18","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1097\/EJA.0000000000000729","article-title":"European guidelines on perioperative venous thromboembolism prophylaxis: executive summary.","volume":"35","author":"Afshari","year":"2018","journal-title":"Eur J Anaesthesiol"},{"issue":"9676","key":"zoi230469r20","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial.","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"issue":"26","key":"zoi230469r21","doi-asserted-by":"publisher","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"issue":"2","key":"zoi230469r23","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1177\/0091270006296058","article-title":"Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects.","volume":"47","author":"Kubitza","year":"2007","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"zoi230469r24","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1111\/ijlh.2018.40.issue-1","article-title":"Effect of rivaroxaban on thrombin generation in vivo: a study in obese patients.","volume":"40","author":"Bertaggia-Calderara","year":"2018","journal-title":"Int J Lab Hematol"},{"issue":"12","key":"zoi230469r25","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1016\/j.soard.2018.08.025","article-title":"The effect of bariatric surgery on the direct oral anticoagulant rivaroxaban: the extension study.","volume":"14","author":"Kr\u00f6ll","year":"2018","journal-title":"Surg Obes Relat Dis"},{"issue":"7","key":"zoi230469r26","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1111\/bcp.v83.7","article-title":"Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery.","volume":"83","author":"Kr\u00f6ll","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"20","key":"zoi230469r27","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"2","key":"zoi230469r28","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1097\/01.sla.0000133083.54934.ae","article-title":"Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey.","volume":"240","author":"Dindo","year":"2004","journal-title":"Ann Surg"},{"issue":"1","key":"zoi230469r29","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1111\/j.1538-7836.2009.03678.x","article-title":"Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients.","volume":"8","author":"Schulman","year":"2010","journal-title":"J Thromb Haemost"},{"issue":"7","key":"zoi230469r30","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1111\/bcp.v83.7","article-title":"Pharmacokinetics and pharmacodynamics of single doses of rivaroxaban in obese patients prior to and after bariatric surgery.","volume":"83","author":"Kr\u00f6ll","year":"2017","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"zoi230469r31","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.soard.2019.02.017","article-title":"Practice patterns regarding post-discharge chemoprophylaxis for venous thromboembolism following bariatric surgery in the United States.","volume":"15","author":"Clark","year":"2019","journal-title":"Surg Obes Relat Dis"},{"issue":"3","key":"zoi230469r32","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.soard.2015.08.505","article-title":"Once versus twice daily injection of enoxaparin for thromboprophylaxis in bariatric surgery: effects on antifactor Xa activity and procoagulant microparticles. A randomized controlled study.","volume":"12","author":"Steib","year":"2016","journal-title":"Surg Obes Relat Dis"},{"issue":"3","key":"zoi230469r33","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/j.soard.2014.10.003","article-title":"The EFFORT trial: preoperative enoxaparin versus postoperative fondaparinux for thromboprophylaxis in bariatric surgical patients: a randomized double-blind pilot trial.","volume":"11","author":"Steele","year":"2015","journal-title":"Surg Obes Relat Dis"},{"issue":"8","key":"zoi230469r34","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1055\/s-0040-1718405","article-title":"Dosage of anticoagulants in obesity: recommendations based on a systematic review.","volume":"46","author":"Abildgaard","year":"2020","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"zoi230469r35","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1381\/09608920160558588","article-title":"Prophylaxis of venous thromboembolism using two different doses of low-molecular-weight heparin (nadroparin) in bariatric surgery: a prospective randomized trial.","volume":"11","author":"Kalfarentzos","year":"2001","journal-title":"Obes Surg"},{"issue":"2","key":"zoi230469r36","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1007\/s11695-013-1105-x","article-title":"Prophylaxis of venous thromboembolism with low molecular weight heparin in bariatric surgery: a prospective, randomised pilot study evaluating two doses of parnaparin (BAFLUX Study).","volume":"24","author":"Imberti","year":"2014","journal-title":"Obes Surg"},{"issue":"1","key":"zoi230469r37","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1177\/1553350620965812","article-title":"Incidence of silent deep venous thrombosis after laparoscopic bariatric surgery in patients who received combined mechanical and chemical thromboprophylaxis compared to patients who received mechanical thromboprophylaxis only.","volume":"28","author":"Ahmad","year":"2021","journal-title":"Surg Innov"},{"key":"zoi230469r38","first-page":"461","article-title":"Prevention of venous thromboembolism in patients undergoing bariatric surgery.","volume":"11","author":"Bartlett","year":"2015","journal-title":"Vasc Health Risk Manag"},{"issue":"6","key":"zoi230469r39","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1097\/SLA.0b013e31825659d4","article-title":"Predicting risk for venous thromboembolism with bariatric surgery: results from the Michigan Bariatric Surgery Collaborative.","volume":"255","author":"Finks","year":"2012","journal-title":"Ann Surg"},{"issue":"6","key":"zoi230469r40","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1097\/SLA.0000000000002126","article-title":"Individualized venous thromboembolism risk stratification using the 2005 Caprini score to identify the benefits and harms of chemoprophylaxis in surgical patients: a meta-analysis.","volume":"265","author":"Pannucci","year":"2017","journal-title":"Ann Surg"},{"issue":"3","key":"zoi230469r41","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00464-018-6348-0","article-title":"Predicting venous thromboembolism following laparoscopic bariatric surgery: development of the BariClot tool using the MBSAQIP database.","volume":"33","author":"Dang","year":"2019","journal-title":"Surg Endosc"},{"issue":"9632","key":"zoi230469r42","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"issue":"6","key":"zoi230469r43","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.7410","article-title":"Safety and efficacy of apixaban vs enoxaparin for preventing postoperative venous thromboembolism in women undergoing surgery for gynecologic malignant neoplasm: a randomized clinical trial.","volume":"3","author":"Guntupalli","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"8","key":"zoi230469r44","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation.","volume":"19","author":"Martin","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"9","key":"zoi230469r45","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1016\/j.amjmed.2017.05.011","article-title":"Influences of obesity and bariatric surgery on the clinical and pharmacologic profile of rivaroxaban.","volume":"130","author":"Moore","year":"2017","journal-title":"Am J Med"},{"issue":"12","key":"zoi230469r46","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1016\/j.amjmed.2021.07.017","article-title":"Oral anticoagulant use in morbid obesity and post bariatric surgery: a review.","volume":"134","author":"Nasser","year":"2021","journal-title":"Am J Med"},{"issue":"6","key":"zoi230469r47","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/jth.13323","article-title":"Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH.","volume":"14","author":"Martin","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"7614","key":"zoi230469r48","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/S0140-6736(69)90002-6","article-title":"Natural history of postoperative deep-vein thrombosis.","volume":"2","author":"Kakkar","year":"1969","journal-title":"Lancet"},{"issue":"5","key":"zoi230469r49","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/jth.12883","article-title":"Diagnosis and treatment of incidental venous thromboembolism in cancer patients: guidance from the SSC of the ISTH.","volume":"13","author":"Di Nisio","year":"2015","journal-title":"J Thromb Haemost"},{"key":"zoi230469r19","unstructured":"National Guideline Centre. Venous Thromboembolism in Over 16s: Reducing the Risk of Hospital-Acquired Deep Vein Thrombosis or Pulmonary Embolism. National Institute for Health and Care Excellence. NICE Guidelines. March 21, 2018. Accessed April 18, 2023. https:\/\/www.nice.org.uk\/guidance\/ng89"},{"key":"zoi230469r22","unstructured":"Bayer Pharma? AG. Xarelto\u00ae (rivaroxaban) summary of product characteristics. Accessed January 10, 2017. https:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000944\/WC500057108.pdf"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2805302\/krll_2023_oi_230469_1684266831.50671.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T11:33:52Z","timestamp":1685014432000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2805302"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":49,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.15241","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,25]]}}}